ERRγ impedes neuroendocrine prostate cancer development
Genes & Development · 2026
DOI: 10.1101/gad.353024.125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes & Development, 2026. Verfasst von Ting Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Goodman Cancer Institute, McGill University, Montréal, Québec H3A 1A3, Canada; vincent.giguere@mcgill.ca tingli@um.edu.mo. Hauptthemen laut MEDLINE: Receptors, Estrogen, Prostatic Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Canadian Institutes of Health Research, Terry Fox Research Institute, Cancer Research Society.
Abstract (Originalsprache)
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer (CRPC). The molecular mechanisms underlying the progression of CRPC toward NEPC remain incompletely understood, and effective treatments remain to be discovered. Here, we report that loss of the nuclear receptor ERRγ promotes neuroendocrine differentiation in a Pten-deficient mouse model of prostate adenocarcinoma. These findings were recapitulated in advanced cellular and xenograft models of human prostate cancer. Critically, we show that ERRγ gain of function can reverse instilled NEPC features accompanied by suppression of growth and oncogenic metabolic reprogramming. Activation of a neuroendocrine transcriptional program enabled by ERRγ deficiency unveiled a targetable vulnerability exploited by the combined pharmacological inhibition of EZH2 and RET kinase that effectively inhibited the growth of ERRγ-deficient tumor organoids and cells. Collectively, our findings demonstrate that ERRγ downregulation facilitates prostate cancer adeno-to-neuroendocrine transformation and offer potential therapeutic strategies to prevent/treat the development of poor outcome NEPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Goodman Cancer Institute, McGill University, Montréal, Québec H3A 1A3, Canada; vincent.giguere@mcgill.ca tingli@um.edu.mo.
- State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, China.
- Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, Macao SAR 999078, China.
- Goodman Cancer Institute, McGill University, Montréal, Québec H3A 1A3, Canada.
- Department of Biochemistry, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec H3G 1Y6, Canada.
- Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao SAR 999078, China.
ORCID-Profile: Ting Li, Catherine R Dufour, Lingwei Han, Anthony Alfonso, Mirna Farhat, Vincent Giguère
Förderung
- Canadian Institutes of Health Research
- Terry Fox Research Institute
- Cancer Research Society
- National Natural Science Foundation of China
- Science and Technology Development Fund, Macau SAR
- Canderel and Fonds de
- Recherche du Québec-Santé
- CIHR
Zitieren
APA
Li, T., Dufour, C. R., Han, L., Alfonso, A., Farhat, M., Beaumier, A., Chen, Q., Lu, J. J., & Giguère, V. (2026). ERRγ impedes neuroendocrine prostate cancer development. Genes & Development. https://doi.org/10.1101/gad.353024.125
Vancouver
Li T, Dufour CR, Han L, Alfonso A, Farhat M, Beaumier A, et al. ERRγ impedes neuroendocrine prostate cancer development. Genes & Development. 2026. doi:10.1101/gad.353024.125
BibTeX
@article{Li2026,
author = {Li, Ting and Dufour, Catherine R and Han, Lingwei and Alfonso, Anthony and Farhat, Mirna and Beaumier, Annabelle and Chen, Qian and Lu, Jin-Jian and Giguère, Vincent},
title = {ERRγ impedes neuroendocrine prostate cancer development},
journal = {Genes & Development},
year = {2026},
doi = {10.1101/gad.353024.125}
}
EUVIMED